Search Results - "Hummers, L K"

Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension by CAMPO, A, MATHAI, S. C, HASSOUN, P. M, LE PAVEC, J, ZAIMAN, A. L, HUMMERS, L. K, BOYCE, D, HOUSTEN, T, LECHTZIN, N, CHAMI, H, GIRGIS, R. E

“…The aim of this study was to examine the causes and outcomes of hospitalisation in patients with pulmonary arterial hypertension (PAH). 205 consecutive…”
Get full text

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension by Mathai, S. C, Bueso, M, Hummers, L. K, Boyce, D, Lechtzin, N, Le Pavec, J, Campo, A, Champion, H. C, Housten, T, Forfia, P. R, Zaiman, A. L, Wigley, F. M, Girgis, R. E, Hassoun, P. M

“…N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of neurohormonal activation that is useful in the diagnosis and prognosis of various forms of…”
Get full text

A case–control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma) by Roberts, C G P, Hummers, L K, Ravich, W J, Wigley, F M, Hutchins, G M

“…Background: Atrophy of the smooth muscle layers of the muscularis propria characterises oesophageal involvement in systemic sclerosis (scleroderma). The…”
Get full text

PM-Scl and Th/To in systemic sclerosis: a comparison of different autoantibody assays by Mecoli, C. A., Gutierrez-Alamillo, L., Yang, Q., Sampedro, M., Woods, A., Hummers, L. K., Wigley, F., Shah, A. A., Casciola-Rosen, L.

“…Objective To compare test characteristics of the Euroimmun line blot assay with other assays for two uncommon autoantibody specificities in systemic…”
Get full text

Recurrent transverse myelitis associates with anti-ro (SSA) autoantibodies by HUMMERS, L. K, KRISHNAN, C, CASCIOLA-ROSEN, L, ROSEN, A, MORRIS, S, MAHONEY, J. A, KERR, D. A, WIGLEY, F. M

“…Transverse myelitis (TM) is an idiopathic inflammatory disorder of the spinal cord. The authors observed cases of recurrent TM in patients where anti-Ro (SSA)…”
Get full text

High-dose cyclophosphamide without stem cell rescue in scleroderma by Tehlirian, C V, Hummers, L K, White, B, Brodsky, R A, Wigley, F M

“…To investigate the safety and tolerability of high-dose cyclophosphamide without stem cell rescue in scleroderma. An open-label, single-site, uncontrolled…”
Get more information

The "tank top sign": a unique pattern of skin fibrosis seen in pansclerotic morphea by Sherber, N S, Boin, F, Hummers, L K, Wigley, F M

Get more information

Biomarkers of vascular disease in scleroderma by Hummers, L. K.

“…Vascular disease is present in every patient with scleroderma and is a major source of morbidity and mortality. There is a subset of patients who will develop…”
Get full text

Abnormal exhaled ethane concentrations in scleroderma by Cope, K. A., Solga, S. F., Hummers, L. K., Wigley, F. M., Diehl, A. M., Risby, T. H.

“…Abstract Scleroderma (systemic sclerosis) is a chronic multisystem autoimmune disease in which oxidative stress is suspected to play a role in the…”
Get full text

Distinct recognition of antibodies to centromere proteins in primary Sjögren’s syndrome compared with limited scleroderma by Gelber, A C, Pillemer, S R, Baum, B J, Wigley, F M, Hummers, L K, Morris, S, Rosen, A, Casciola-Rosen, L

“…Background: Anticentromere antibodies are characteristically observed in scleroderma but have recently been reported in other autoimmune rheumatic disorders,…”
Get full text

Distinct clinical trajectories of gastrointestinal progression among patients with systemic sclerosis by Perin, J, Hughes, M, Mecoli, C A, Paik, J J, Gelber, A C, Wigley, F M, Hummers, L K, Shah, A A, Zeger, S L, McMahan, Z H

“…Systemic sclerosis (SSc) is heterogeneous in its clinical presentation. Common manifestations cluster together, defining unique subgroups. This investigation…”
Get full text

Troponin elevation independently associates with mortality in systemic sclerosis by Paik, Julie J, Choi, Deborah Y, Mukherjee, Monica, Hsu, Steven, Wigley, Fredrick, Shah, Ami A, Hummers, Laura K

“…Cardiac involvement is common in systemic sclerosis (SSc), and elevated troponin may be the only sign of ongoing myocardial disease. The objective was to…”
Get more information

The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation by Luebker, Sarah, Frech, Tracy M, Assassi, Shervin, Gordon, Jessica K, Bernstein, Elana J, Steen, Virginia D, Shah, Ami A, Hummers, Laura K, Richardson, Carrie, Khanna, Dinesh, Castelino, Flavia V, Chung, Lorinda, Hant, Faye N, Shanmugam, Victoria K, VanBuren, John M, Alvey, Jessica, Harding, Monica, Sandorfi, Nora

“…Systemic Sclerosis (SSc) is frequently associated with gastrointestinal tract (GIT) involvement. The Collaborative National Quality and Efficacy Registry…”
Get more information

D17 SIGN "O" THE TIMES: DIAGNOSIS AND RISK STRATIFICATION OF PULMONARY HYPERTENSION: Validation Of The Reveal Registry Prognostic Equation And Risk Score Calculator In Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension by Mullin, C J, Khair, R, Damico, R L, Kolb, T M, Hummers, L K, Hassoun, P M, Steen, V, Mathai, S

“…A prognostic equation and risk score calculator derived from the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) have been developed…”
Get full text

Evaluation of cancer-associated myositis and scleroderma autoantibodies in breast cancer patients without rheumatic disease by Shah, Ami A, Rosen, Antony, Hummers, Laura K, May, Betty J, Kaushiva, Alpana, Roden, Richard B S, Armstrong, Deborah K, Wigley, Fredrick M, Casciola-Rosen, Livia, Visvanathan, Kala

“…Systemic sclerosis (scleroderma) and dermatomyositis are two prototypic autoimmune diseases that are strongly associated with malignancy. While specific…”
Get full text

Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry by Chung, Lorinda, Fairchild, Robert M, Furst, Daniel E, Li, Shufeng, Alkassab, Firas, Bolster, Marcy B, Csuka, Mary Ellen, Derk, Chris T, Domsic, Robyn T, Fischer, Aryeh, Frech, Tracy M, Gomberg-Maitland, Mardi, Gordon, Jessica K, Hinchcliff, Monique, Hsu, Vivien, Hummers, Laura K, Khanna, Dinesh, Medsger, Thomas A Jr, Molitor, Jerry A, Preston, Ivana R, Schiopu, Elena, Shapiro, Lee, Hant, Faye, Silver, Richard, Simms, Robert, Varga, John, Steen, Virginia D, Zamanian, Roham T

“…To assess the utility of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) in detecting and monitoring pulmonary hypertension (PH) in…”
Get full text

A40 CONNECTIVE TISSUE DISEASE RELATED INTERSTITIAL LUNG DISEASE: RISK FACTORS, DIAGNOSIS, AND OUTCOMES: Pulmonary Hypertension And Interstitial Lung Disease Within Pharos: Impact Of Extent Of Fibrosis And Pulmonary Physiology On Cardiac Hemodynamic Parameters by Fischer, A, Mathai, S C, Bolster, M, Chung, L, Csuka, M, Domsic, R, Frech, T, Hinchcliff, M, Kolfenbach, J, Hummers, L K, Gomberg-Maitland, M, Hsu, V, Simms, R, Steen, V

Get full text

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters by Fischer, A, Swigris, J J, Bolster, M B, Chung, L, Csuka, M E, Domsic, R, Frech, T, Hinchcliff, M, Hsu, V, Hummers, L K, Gomberg-Maitland, M, Mathai, S C, Simms, R, Steen, V D

“…We sought to examine the relationship between measures of ILD severity and PH in patients with SSc. We identified 55 subjects from 12 PHAROS sites with…”
Get full text

Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: Impact of pulmonary arterial hypertension therapies by Le Pavec, Jérôme, Girgis, Reda E., Lechtzin, Noah, Mathai, Stephen C., Launay, David, Hummers, Laura K., Zaiman, Ari, Sitbon, Olivier, Simonneau, Gérald, Humbert, Marc, Hassoun, Paul M.

“…Objective Precapillary pulmonary hypertension (PH) is an important cause of death in patients with systemic sclerosis (SSc). It can occur in isolation…”
Get full text

Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis by Le, Elizabeth N, Wigley, Fredrick M, Shah, Ami A, Boin, Francesco, Hummers, Laura K

“…Immunosuppressive therapy may potentially alter the natural disease course of scleroderma. There have been reports of using mycophenolate mofetil (MMF) for the…”
Get more information